AstraZeneca Stock Price, News & Analysis (NYSE:AZN)

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca declared a semiannual dividend on Friday, February 15th. Investors of record on Friday, March 1st will be paid a dividend of $0.95 per share on Wednesday, March 27th. This represents a yield of 4.64%. The ex-dividend date of this dividend is Thursday, February 28th. This is an increase from AstraZeneca's previous semiannual dividend of $0.45. View AstraZeneca's Dividend History.

Shares of AstraZeneca split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

AstraZeneca plc (NYSE:AZN) posted its quarterly earnings results on Thursday, July, 25th. The company reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.30 by $0.43. The company earned $5.72 billion during the quarter, compared to analyst estimates of $5.57 billion. AstraZeneca had a return on equity of 35.83% and a net margin of 9.38%. The firm's quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.69 earnings per share. View AstraZeneca's Earnings History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for AstraZeneca.

AstraZeneca issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share (EPS) guidance of $3.50-3.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.54.

18 analysts have issued 1 year price objectives for AstraZeneca's stock. Their predictions range from $40.73 to $50.00. On average, they anticipate AstraZeneca's stock price to reach $46.12 in the next twelve months. This suggests a possible upside of 4.9% from the stock's current price. View Analyst Price Targets for AstraZeneca.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

Media headlines about AZN stock have been trending somewhat positive on Tuesday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AstraZeneca earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for AstraZeneca.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), AbbVie (ABBV), Eli Lilly And Co (LLY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include AT&T (T), Pfizer (PFE), AbbVie (ABBV), Bank of America (BAC), Cisco Systems (CSCO), Gilead Sciences (GILD), Merck & Co., Inc. (MRK), Micron Technology (MU), Intel (INTC) and General Electric (GE).

AstraZeneca's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Park National Corp OH (0.01%), Crossmark Global Holdings Inc. (0.00%), Gradient Investments LLC (0.00%), TIAA FSB (0.00%), Town & Country Bank & Trust CO dba First Bankers Trust CO (0.00%) and Pacer Advisors Inc. (0.00%). View Institutional Ownership Trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Gradient Investments LLC, Town & Country Bank & Trust CO dba First Bankers Trust CO and TIAA FSB. View Insider Buying and Selling for AstraZeneca.

AZN stock was purchased by a variety of institutional investors in the last quarter, including Park National Corp OH, Pacer Advisors Inc., Henry James International Management Inc., RB Capital Management LLC and Private Trust Co. NA. View Insider Buying and Selling for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $43.98.

AstraZeneca has a market capitalization of $115.39 billion and generates $22.09 billion in revenue each year. The company earns $2.16 billion in net income (profit) each year or $1.73 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]